Gainers
- Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.
- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 49.3% to $0.2852. Allena Pharmaceuticals recently announced it has terminated its previously announced at-the-market offering.
- Inter & Co, Inc. (NASDAQ: INTR) gained 31.9% to $2.77. Goldman Sachs (NYSE:GS) recently initiated coverage on the stock with a Sell rating.
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) gained 28% to $0.4521 after the company executed an agreement to terminate its vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical. The company will receive a $55 million settlement fee.
- Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) shares climbed 25.2% to $5.21. Lytus recently announced the closing of initial public offering.
- ECMOHO Limited (NASDAQ: MOHO) rose 24.8% to $0.2049 after dropping over 4% on Thursday.
- Fast Radius, Inc. (NASDAQ: FSRD) rose 22.3% to $0.7699 after jumping over 37% on Thursday. Fast Radius recently appointed Pat McCusker as President, Interim CFO and John Nanry as COO.
- Larimar Therapeutics, Inc. (NASDAQ: LRMR) gained 20.9% to $2.37.
- Shift Technologies, Inc. (NASDAQ: SFT) rose 20.1% to $0.8086 after declining around 7% on Thursday.
- Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) surged 19.2% to $3.10.
- VerifyMe, Inc. (NASDAQ: VRME) shares gained 18.6% to $2.3250 after the company announced liquidation of the G3 VRM Acquisition SPAC and initiated a new share repurchase program.
- Accolade, Inc. (NASDAQ: ACCD) surged 18.2% to $8.74 after the company reported better-than-expected Q1 results.
- Borqs Technologies, Inc. (NASDAQ: BRQS) jumped 17.3% to $1.9699 after the company announced its subsidiary, Holu Hou Energy, signed $49.8 million of contracts in Q2 in the State of Hawaii.
- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) gained 17.2% to $2.04.
- Coupang, Inc. (NYSE: CPNG) gained 15.9% to $14.77 after Credit Suisse (SIX:CSGN) upgraded the stock from Neutral to Outperform.
- Aspira Women's Health Inc. (NASDAQ: AWH) rose 14% to $0.6699.
- LightInTheBox Holding Co., Ltd. (NYSE: LITB) gained 13% to $1.0850. LightInTheBox recently posted Q1 sales of $93.77 million.
- Sonder Holdings Inc. (NASDAQ: SOND) shares surged 12.5% to $1.17.
- Cosmos Holdings Inc. (NASDAQ: COSM) gained 12.1% to $0.4191. Cosmos Holdings reported a strategic R&D partnership with Cloudpharm P.C. to study the human gastrointestinal microbiome and launch related products targeting on obesity and other gut-related disorders.
- Missfresh Limited (NASDAQ: MF) shares rose 11.1% to $0.2833 after declining around 10% on Thursday.
- Engine Gaming and Media, Inc. (NASDAQ: GAME) gained 11.1% to $0.90.
- Omeros Corporation (NASDAQ: OMER) rose 10.8% to $3.05.
- Tenax Therapeutics, Inc. (NASDAQ: TENX) gained 10% to $0.3299.
- Etsy, Inc. (NASDAQ: ETSY) surged 9.1% to $79.85. Evercore ISI Group maintained Etsy with an Outperform and lowered the price target from $130 to $95.
- Missfresh Limited (NASDAQ: MF) gained 9% to $0.2780.
- Synchronoss Technologies, Inc. (NASDAQ: SNCR) surged 8.3% to $1.2450.
- OceanPal Inc. (NASDAQ: OP) rose 5% to $0.50. OceanPal recently announced entry into agreement to acquire capesize dry bulk vessel.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
- Talaris Therapeutics, Inc. (NASDAQ: TALS) shares dropped 49.4% to $2.28. SVB Leerink downgraded Talaris Therapeutics from Outperform to Market Perform and lowered the price target from $21 to $7.
- Agile Therapeutics, Inc. (NASDAQ: AGRX) fell 44% to $0.6497 after the company priced a 26,666,666 share common stock offering at $0.90 per share.
- ioneer Ltd (NASDAQ: IONR) fell 29% to $12.51.
- Ensysce Biosciences, Inc. (NASDAQ: ENSC) fell 27.4% to $0.6305 after jumping around 73% on Thursday.
- Kohl's Corporation (NYSE: NYSE:KSS) shares fell 21.3% to $28.10 after the company called off discussions to sell its business to Franchise Group Inc.
- MMTec, Inc. (NASDAQ: MTC) dropped 20.8% to $0.2336.
- Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares fell 20% to $0.5199 after jumping around 20% on Thursday.
- Cryptyde, Inc. (NASDAQ: TYDE) dropped 18.2% to $1.66.
- Borr Drilling Limited (NYSE: BORR) fell 18% to $3.78 after dropping 15% on Thursday.
- Celldex Therapeutics, Inc. (NASDAQ: CLDX) fell 16.9% to $22.41 after the company presented interim data from its Barzolvolimab Phase 1b study at EAACI 2022.
- Endo International plc (NASDAQ: ENDP) fell 14.4% to $0.3976 after the company announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with adhesive capsulitis (AC) of the shoulder (frozen shoulder).
- Yoshitsu Co., Ltd (NASDAQ: TKLF) dropped 14.2% to $1.45.
- Acutus Medical, Inc. (NASDAQ: AFIB) declined 14% to $0.9638. Acutus Medical recently announced the commercial launch of its left-heart access products.
- ThermoGenesis Holdings, Inc. (NASDAQ: THMO) fell 13.3% to $0.2392.
- Evofem Biosciences, Inc. (NASDAQ: EVFM) dropped 12.3% to $0.99.
- Jiuzi Holdings, Inc. (NASDAQ: JZXN) fell 12.1% to $0.7713.
- Kalera Public Limited Company (NASDAQ: KAL) dropped 10.4% to $5.28.
- Amarin Corporation plc (NASDAQ: AMRN) fell 9.4% to $1.35. Amarin announced REDUCE-IT exploratory post hoc biomarker sub-analysis showed relatively small changes in inflammatory markers between icosapent ethyl and placebo.
- Revelation Biosciences, Inc. (NASDAQ: REVB) fell 7.2% to $1.03 after jumping 77% on Thursday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for treatment of allergic rhinitis.
- Biophytis S.A. (NASDAQ: BPTS) shares fell 7% to $1.00 after the company announced the drawing of the second tranche of Ornane under the 2021 Atlas contract for €4 million.
- Micron Technology, Inc. (NASDAQ: NASDAQ:MU) fell 5.4% to $52.28. Micron reported upbeat financial results for its third quarter, but issued weak guidance for its fourth quarter.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Read at Benzinga